<DOC>
	<DOCNO>NCT03076151</DOCNO>
	<brief_summary>Tacrolimus calcineurin inhibitor widely use prevention allograft rejection solid organ bone marrow transplantation . It characterize narrow therapeutic index large inter-individual pharmacokinetic variability . Adoport速 immediate-release formulation tacrolimus , administer twice daily . Because narrow therapeutic window well correlation pre-dose level effect dose effect , therapeutic drug monitoring ( TDM ) base trough whole blood tacrolimus concentration recommend Adoport速 . TDM help minimize risk acute rejection occurrence adverse effect ( mainly nephrotoxicity , less extent , neurotoxicity ) . As report consensus document consortium European expert tacrolimus TDM , interdose area-under-the curve ( AUC0-12h ) expect best marker tacrolimus exposure . However , tacrolimus monitoring base full AUC0-12h difficult set routine , due clinical constraint necessity multiple sample . Calculation AUC0-12h use Bayesian estimation limit sample strategy , i.e . blood sample collect early phase post-dose would represent elegant solution , already do tacrolimus formulation . Furthermore , pharmacokinetics ( PK ) tacrolimus influence single nucleotide polymorphism within intron 3 cytochrome P450 3A5 ( CYP3A5 ) . Patients carry least one CYP3A5*1 allele consider CYP3A5 expressors ( 12 % Caucasian population , Hapmap project ) thus require 1.5 2-fold high start dose CYP3A5*3/*3 carrier reach predefined target exposure early transplantation . Although polymorphism show impact performance Bayesian estimator previously develop tacrolimus formulation , patient status CYP3A5*3 consider pharmacokinetic study potential covariate , confound factor , PK model . Specifically , owe 12 % frequency White European population , 4 patient carrier CYP3A5*1 allele expect study ; performance PK model Bayesian estimator develop specifically evaluate subgroup .</brief_summary>
	<brief_title>Pharmacokinetic Study Adoport速 ( Tacrolimus ) Patients With de Novo Kidney Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . Subject 's write informed consent study 2 . Male female ( &gt; = 18 year ) 3 . Recipients first kidney allograft 4 . Patients transplant less 7 day enrolment 5 . Patients affiliate social security system 1 . Patients present contraindication tacrolimus accord summary product characteristic Adoport速 2 . Patient present antiHLA antibody graft pretransplantation ( DSA ) 3 . Recipients transplant organ kidney 4 . Pregnant ( positive BHCG test ) lactate woman 5 . Women without method contraception , except woman childbearing potential ( accord guideline work group , Clinical Trial Facilitation Group , relate contraception pregnancy test clinical trial ) 6 . Patients participate interventional clinical study inclusion well whole course current study 7 . Patient judicial protection 8 . Patients incapable understanding purpose risk study , give write informed consent , unwilling comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Transplantation</keyword>
	<keyword>Kidney</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>bayesian estimator</keyword>
</DOC>